Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 28 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

High-dose interferon with ribavirin may be suitable for non-responders to conventional interferon mono-therapy for hepatitis C

High-dose interferon with ribavirin appears to be a therapeutic option for non-responders to conventional interferon mono-therapy, according to a report published in the March issue of Alimentary Pharmacology and Therapeutics.

News image

fiogf49gjkf04

Conventional interferon mono-therapy fails to achieve virological clearance in most hepatitis C-infected patients.

The use of high-dose induction regimens has been suggested to improve the initial clearance of virus, while the addition of ribavirin appears to improve the rates of sustained response once clearance is achieved.

The efficacy and safety of re-treatment with an induction regimen of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon mono-therapy was assessed by Dr A.H. Malik and colleagues.

The research group, based at the Division of Digestive and Liver Diseases at the University of Texas Southwestern Medical Center in Dallas, Texas, USA, recruited previous virological non-responders to standard dose interferon (3-5 MU three times weekly for 12 weeks).

These patients were randomized into two groups, A and B.

Group A received, unblind, 10 MU interferon alpha-2b daily for 10 weeks, then 5 MU daily for 74 days, then 5 MU three times weekly for 24 weeks (total 36 weeks)

Interferon alpha-2b plus ribavirin - 33% sustained response rate
Alimentary Pharmacology and Therapeutics

The second group received the above regimen with the addition of ribavirin, 1000-1200 mg/day, at Day 11 (Group B).

All patients were followed up for 24 weeks after completion of therapy.

At the end of treatment, the virological response was noted in one of ten (10%) patients in Group A and in 8 of 15 (54%) patients in Group B.

The sole end treatment responder in Group A and three in Group B relapsed on follow-up.

The apparent improvement in response in Group B compared to Group A nearly reached statistical significance (Group B 5/15 vs. Group A 0/10; P = 0.06).

The research group concluded that a 36-week high-dose induction interferon mono-therapy did not yield sustained responses in previous non-responders to standard dose interferon.

However, the same regimen with ribavirin yielded a 33% sustained response rate, nearly reaching statistical significance.

Dr Malik, speaking on behalf of his fellow authors, commented, "The therapy was well tolerated, despite the higher doses of interferon used and the addition of ribavirin.

He concluded, "High-dose interferon with ribavirin appears to be a therapeutic option for non-responders to conventional interferon mono-therapy."

Aliment Pharmacol Ther 2002; 16(3) 381-388
12 March 2002

Go to top of page Email this page Email this page to a colleague

 28 May 2018 
Therapeutic strategies for HCV
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us